title: Bevacizumab is safe in acute relapses of neuromyelitis optica.
abstract: OBJECTIVE
  Neuromyelitis optica (NMO) is a relapsing autoimmune disease targeting the spinal cord and optic nerve leading to paralysis and blindness. Current treatment for acute NMO attacks is immunosuppression with high-dose corticosteroids and/or plasmapheresis. Preclinical animal studies suggest that bevacizumab might be beneficial in limiting the extent of inflammation during a NMO relapse by reducing the disruption of the blood-brain barrier.
  
  
  METHODS
  We carried out an open-label phase 1b safety and proof-of-concept trial in 10 participants with NMO immunoglobulin G seropositive NMO, NMO spectrum disease and those at high risk for developing NMO/NMO spectrum disease who presented with an acute attack of transverse myelitis, optic neuritis or brainstem inflammation. In addition to treating with 1 g of daily intravenous methylprednisolone, we infused 10 mg/kg of bevacizumab intravenously on day 1 of treatment. The primary outcome measure was safety and the secondary outcome measure was efficacy.
  
  
  RESULTS
  Of the 10 participants enrolled, five presented with acute transverse myelitis, four with acute optic neuritis and one with a brainstem lesion. Bevacizumab was safe in all 10 participants, with only one serious adverse event within the 90-day follow up that was not attributed to the medication. Three patients recovered to pre-attack neurological function or better, and no patients required escalation to plasmapheresis.
  
  
  CONCLUSIONS
  Bevacizumab is a safe add-on therapy to high-dose corticosteroids for NMO/NMO spectrum disease patients presenting with an acute relapse.
authors.affiliation: Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
authors.forename: Maureen A
authors.initials: MA
authors.lastname: Mealy
authors.affiliation: Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
authors.forename: Kyong
authors.initials: K
authors.lastname: Shin
authors.affiliation: Department of Neurology, Mount Sinai Hospital, New York, NY, USA.
authors.forename: Gareth
authors.initials: G
authors.lastname: John
authors.affiliation: Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Levy
keywords: aquaporin-4; bevacizumab; neuromyelitis optica; vascular endothelial growth factor
references.citation: Disabil Rehabil. 2014;36(13):1100-7
references.pmid: 24028351
references.citation: J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):288-97
references.pmid: 22100760
references.citation: Rinsho Shinkeigaku. 2009 Nov;49(11):894-5
references.pmid: 20030241
references.citation: Neurology. 2006 May 23;66(10 ):1485-9
references.pmid: 16717206
references.citation: Neurology. 1999 Sep 22;53(5):1107-14
references.pmid: 10496275
references.citation: Arch Neurol. 2007 Jun;64(6):899-901
references.pmid: 17562942
references.citation: Lancet Neurol. 2007 Sep;6(9):805-15
references.pmid: 17706564
references.citation: Mult Scler Relat Disord. 2012 Oct;1(4):180-187
references.pmid: 24555176
references.citation: Neurology. 2011 Jan 4;76(1):87-93
references.pmid: 21205697
references.citation: J Clin Invest. 2012 Jul;122(7):2454-68
references.pmid: 22653056
references.citation: Drugs. 2014 Oct;74(16):1891-925
references.pmid: 25315029